Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936663 · ClinicalTrials.gov registry record · Phase 4
Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
A Phase 4 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT00936663 is a Phase 4 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 3 participants.
The verdict
NCT00936663, a Phase 4 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-07-06 |
| Est. Completion | 2010-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936663
The ClinicalTrials.gov registry entry for NCT00936663 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00936663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936663 about?
NCT00936663 is a clinical study titled "Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation". This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.
What is the current status of trial NCT00936663?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2009-07-06. Estimated completion is 2010-06-01.
What interventions are being tested in trial NCT00936663?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT00936663?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.